Dublin, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The "Obesity: Competitive Landscape to 2026" report has been added to ResearchAndMarkets.com's offering.

This report provides an assessment of the pipeline, clinical, and commercial landscape of Obesity. Overall, The researchers expect that the approval of new long-acting GLP-1R and dual GLP-1R/GCGR agonists, and a novel appetite reducing drug will drive Obesity market growth during the next decade.

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
• Commercial Assessment: leading marketed products, current and future players
• Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Obesity market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Obesity market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1. Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports

2. Executive Summary
2.1 Key Findings
2.2 Key Events

3. Introduction
3.1 Report Scope
3.2 Disease Overview and Epidemiology

4. Pipeline Assessment
4.1 Pipeline Overview
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Molecule Type and Target
4.4 Drug Review Designations
4.5 Products in Clinical Development

5. Clinical Trial Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in Obesity
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics

6 Commercial Assessment
6.1 Leading Marketed Products
6.2 Current & Future Players

7. Competitive Landscape Analysis (2016-2026)
7.1 Events Classification Overview
7.2 US
7.3 5EU
7.4 Japan
7.5 China

8 Appendix

Companies Mentioned

• Novo Nordisk
• Pernix Therapeutics
• Nalpropion Pharmaceuticals
• Sanofi
• AstraZeneca
• MedImmune
• Hanmi Pharmaceuticals
• OPKO Health
• Rhythm Pharmaceuticals
• Eisai
• GlaxoSmithKline
• Roche
• Vivus
• Takeda
• Taisho Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/tm47xd/global_obesity?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Anti-Obesity Drugs